FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155504662> ?p ?o ?g. }

• W2155504662 abstract "Osteoarthritis (OA) is the most common form of arthritis and is caused by degeneration of the joint cartilage and growth of new bone, cartilage and connective tissue. It is often associated with major disability and impaired quality of life. There is currently no consensus on the best treatment to improve OA symptoms. Celecoxib is a selective non-steroidal anti-inflammatory drug (NSAID).To assess the clinical benefits (pain, function, quality of life) and safety (withdrawals due to adverse effects, serious adverse effects, overall discontinuation rates) of celecoxib in osteoarthritis (OA).We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and clinical trials registers up to April 11, 2017, as well as reference and citation lists of included studies. Pharmaceutical companies and authors of published articles were contacted.We included published studies (full reports in a peer reviewed journal) of prospective randomized controlled trials (RCTs) that compared oral celecoxib versus no intervention, placebo or another traditional NSAID (tNSAID) in participants with clinically- or radiologically-confirmed primary OA of the knee or hip, or both knee and hip.Two authors independently performed data extraction, quality assessment, and compared results. Main analyses for patient-reported outcomes of pain and physical function were conducted on studies with low risk of bias for sequence generation, allocation concealment and blinding of participants and personnel.We included 36 trials that provided data for 17,206 adults: 9402 participants received celecoxib 200 mg/day, and 7804 were assigned to receive either tNSAIDs (N = 1869) or placebo (N = 5935). Celecoxib was compared with placebo (32 trials), naproxen (6 trials) and diclofenac (3 trials). Studies were published between 1999 and 2014. Studies included participants with knee, hip or both knee and hip OA; mean OA duration was 7.9 years. Most studies included predominantly white participants whose mean age was 62 (± 10) years; most participants were women. There were no concerns about risk of bias for performance and detection bias, but selection bias was poorly reported in most trials. Most trials had high attrition bias, and there was evidence of selective reporting in a third of the studies. Celecoxib versus placeboCompared with placebo celecoxib slightly reduced pain on a 500-point Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain scale, accounting for 3% absolute improvement (95% CI 2% to 5% improvement) or 12% relative improvement (95% CI 7% to 18% improvement) (4 studies, 1622 participants). This improvement may not be clinically significant (high quality evidence).Compared with placebo celecoxib slightly improved physical function on a 1700-point WOMAC scale, accounting for 4% absolute improvement (95% CI 2% to 6% improvement), 12% relative improvement (95% CI 5% to 19% improvement) (4 studies, 1622 participants). This improvement may not be clinically significant (high quality evidence).There was no evidence of an important difference for withdrawals due to adverse events (Peto OR 0.99, 95% CI 0.85 to 1.15) (moderate quality evidence due to study limitations).Results were inconclusive for numbers of participants experiencing any serious AEs (SAEs) (Peto OR 0.95, 95% CI 0.66 to 1.36), gastro-intestinal events (Peto OR 1.91, 95% CI 0.24 to 14.90) and cardiovascular events (Peto OR 3.40, 95% CI 0.73 to 15.88) (very low quality evidence due to serious imprecision and study limitations). However, regulatory agencies have warned of increased cardiovascular events for celecoxib. Celecoxib versus tNSAIDsThere were inconclusive results regarding the effect on pain between celecoxib and tNSAIDs on a 100-point visual analogue scale (VAS), showing 5% absolute improvement (95% CI 11% improvement to 2% worse), 11% relative improvement (95% CI 26% improvement to 4% worse) (2 studies, 1180 participants, moderate quality evidence due to publication bias).Compared to a tNSAID celecoxib slightly improved physical function on a 100-point WOMAC scale, showing 6% absolute improvement (95% CI 6% to 11% improvement) and 16% relative improvement (95% CI 2% to 30% improvement). This improvement may not be clinically significant (low quality evidence due to missing data and few participants) (1 study, 264 participants).Based on low or very low quality evidence (downgraded due to missing data, high risk of bias, few events and wide confidence intervals) results were inconclusive for withdrawals due to AEs (Peto OR 0.97, 95% CI 0.74 to 1.27), number of participants experiencing SAEs (Peto OR 0.92, 95% CI 0.66 to 1.28), gastro-intestinal events (Peto OR 0.61, 0.15 to 2.43) and cardiovascular events (Peto OR 0.47, 95% CI 0.17 to 1.25).In comparisons of celecoxib and placebo there were no differences in pooled analyses between our main analysis with low risk of bias and all eligible studies. In comparisons of celecoxib and tNSAIDs, only one outcome showed a difference between studies at low risk of bias and all eligible studies: physical function (6% absolute improvement in low risk of bias, no difference in all eligible studies).No studies included in the main comparisons measured quality of life. Of 36 studies, 34 reported funding by drug manufacturers and in 34 studies one or more study authors were employees of the sponsor.We are highly reserved about results due to pharmaceutical industry involvement and limited data. We were unable to obtain data from three studies, which included 15,539 participants, and classified as awaiting assessment. Current evidence indicates that celecoxib is slightly better than placebo and some tNSAIDs in reducing pain and improving physical function. We are uncertain if harms differ among celecoxib and placebo or tNSAIDs due to risk of bias, low quality evidence for many outcomes, and that some study authors and Pfizer declined to provide data from completed studies with large numbers of participants. To fill the evidence gap, we need to access existing data and new, independent clinical trials to investigate benefits and harms of celecoxib versus tNSAIDs for people with osteoarthritis, with longer follow-up and more direct head-to-head comparisons with other tNSAIDs." @default.
• W2155504662 created "2016-06-24" @default.
• W2155504662 creator A5022067453 @default.
• W2155504662 creator A5032501163 @default.
• W2155504662 creator A5034002650 @default.
• W2155504662 creator A5037059643 @default.
• W2155504662 creator A5049985810 @default.
• W2155504662 creator A5072335537 @default.
• W2155504662 date "2017-05-22" @default.
• W2155504662 modified "2023-10-18" @default.
• W2155504662 title "Celecoxib for osteoarthritis" @default.
• W2155504662 cites W14215417 @default.
• W2155504662 cites W1501801920 @default.
• W2155504662 cites W1546114942 @default.
• W2155504662 cites W1552860920 @default.
• W2155504662 cites W1561158727 @default.
• W2155504662 cites W1582882063 @default.
• W2155504662 cites W1599185368 @default.
• W2155504662 cites W1642863804 @default.
• W2155504662 cites W1659026544 @default.
• W2155504662 cites W1714980748 @default.
• W2155504662 cites W1812712812 @default.
• W2155504662 cites W1917673874 @default.
• W2155504662 cites W1945695150 @default.
• W2155504662 cites W1963887346 @default.
• W2155504662 cites W1964533656 @default.
• W2155504662 cites W1967057044 @default.
• W2155504662 cites W1968499632 @default.
• W2155504662 cites W1969798546 @default.
• W2155504662 cites W1971273396 @default.
• W2155504662 cites W1973371445 @default.
• W2155504662 cites W1982017315 @default.
• W2155504662 cites W1983104516 @default.
• W2155504662 cites W1984943087 @default.
• W2155504662 cites W1985247069 @default.
• W2155504662 cites W1988145586 @default.
• W2155504662 cites W1989028508 @default.
• W2155504662 cites W1990986050 @default.
• W2155504662 cites W1991339577 @default.
• W2155504662 cites W1991350847 @default.
• W2155504662 cites W1992824602 @default.
• W2155504662 cites W1993961357 @default.
• W2155504662 cites W1996390771 @default.
• W2155504662 cites W1997477176 @default.
• W2155504662 cites W1997642392 @default.
• W2155504662 cites W1999390827 @default.
• W2155504662 cites W2001309417 @default.
• W2155504662 cites W2004210035 @default.
• W2155504662 cites W2007591753 @default.
• W2155504662 cites W2010818945 @default.
• W2155504662 cites W2010899039 @default.
• W2155504662 cites W2012920835 @default.
• W2155504662 cites W2017304854 @default.
• W2155504662 cites W2021075645 @default.
• W2155504662 cites W2023599285 @default.
• W2155504662 cites W2023622543 @default.
• W2155504662 cites W2024697358 @default.
• W2155504662 cites W2027923358 @default.
• W2155504662 cites W2030838816 @default.
• W2155504662 cites W2033058059 @default.
• W2155504662 cites W2034092444 @default.
• W2155504662 cites W2035709184 @default.
• W2155504662 cites W2038410983 @default.
• W2155504662 cites W2040872866 @default.
• W2155504662 cites W2044271090 @default.
• W2155504662 cites W2049609735 @default.
• W2155504662 cites W2054706845 @default.
• W2155504662 cites W2055728946 @default.
• W2155504662 cites W2055841596 @default.
• W2155504662 cites W2057647525 @default.
• W2155504662 cites W2057981214 @default.
• W2155504662 cites W2058308726 @default.
• W2155504662 cites W2060943766 @default.
• W2155504662 cites W2062991772 @default.
• W2155504662 cites W2063738853 @default.
• W2155504662 cites W2068984440 @default.
• W2155504662 cites W2070600819 @default.
• W2155504662 cites W2075950688 @default.
• W2155504662 cites W2079375245 @default.
• W2155504662 cites W2083464592 @default.
• W2155504662 cites W2083582055 @default.
• W2155504662 cites W2089414790 @default.
• W2155504662 cites W2090166425 @default.
• W2155504662 cites W2091561837 @default.
• W2155504662 cites W2095127972 @default.
• W2155504662 cites W2101211236 @default.
• W2155504662 cites W2101592854 @default.
• W2155504662 cites W2102526359 @default.
• W2155504662 cites W2103600429 @default.
• W2155504662 cites W2105341770 @default.
• W2155504662 cites W2105352739 @default.
• W2155504662 cites W2107178532 @default.
• W2155504662 cites W2107673625 @default.
• W2155504662 cites W2112106763 @default.
• W2155504662 cites W2117383908 @default.
• W2155504662 cites W2117896603 @default.
• W2155504662 cites W2117950795 @default.
• W2155504662 cites W2118432230 @default.
• W2155504662 cites W2118836747 @default.
• W2155504662 cites W2118840514 @default.

• next